Sprint Bioscience AB
ABActiveOrg 5567897557Hälsovägen 7, 141 57 HuddingeResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2009 · 16 years old41 employees
Loading company…
Overview
Sprint Bioscience AB is a Swedish AB based in Huddinge, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2009, the company has 41 employees and reported revenue of SEK 167.2m in its latest annual filing.
Revenue 2025
167.2M SEK
+155% vs 2024
EBITDA margin
58.8 %
+626% vs 2024
Net profit 2025
91.7M SEK
+602% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
87.2 %
StrongAmong the 30% highest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
7.6×
StrongAmong the 30% highest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
67.1 %
Very strongAmong the 10% highest rated companies in the industry
20212025
EBITDA — year on year
SEK millionsKey figures
Annual report 2025| Revenue | 167.2M SEK | +155% |
| EBITDA | 98.4M SEK | +626% |
| Net profit | 91.7M SEK | +602% |
| Total assets | 136.7M SEK | +225% |
| Equity | 119.2M SEK | +1185% |
| Employees | 41 | — |
Company information
Legal name
Sprint Bioscience AB
Org number
5567897557
Legal form
Aktiebolag
Founded
28 September 2009 · 16 years
Share capital
SEK 7,070,000
Employees
41 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckling av läkemedel och därmed förenlig verksamhet.
(no translation available)
Contact
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Sprint Bioscience AB reported revenue of SEK 167.2m, an increase of 155% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of SEK 91.7m, and the EBITDA margin stood at 58.8%.
At the end of 2025, equity financed 87.2% of the balance sheet, and current assets covered short-term debt 7.6 times.
Financials
Revenue
SEK millionsEBITDA
SEK millionsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 167,168 | 65,641 | 50,485 | 83 | 35,114 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 98,365 | -18,710 | -398 | -60,122 | -25,038 |
| Depreciation & amort. | -1,074 | -958 | -447 | -618 | -590 |
| EBIT | 97,291 | -19,668 | -845 | -60,740 | -25,628 |
| Net financials | -5,555 | 1,391 | 407 | 571 | 545 |
| Profit before tax | 91,736 | -18,277 | -438 | -60,170 | -25,083 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 91,736 | -18,277 | -438 | -60,170 | -25,083 |
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 136,661 | 42,055 | 62,377 | 37,422 | 79,137 |
| Equity | 119,177 | 9,272 | 27,774 | 28,188 | 70,454 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 17,484 | 32,783 | 34,603 | 9,234 | 8,683 |
| Total debt | 17,484 | 32,783 | 34,603 | 9,234 | 8,683 |
Financial ratios
5-year trendEBITDA margin
58.8 %
20212025
Equity ratio
87.2 %
StrongAmong the 30% highest rated companies in the industry
20212025
Return on equity
77.0 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Net profit margin
54.9 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Asset turnover
1.22×
StrongAmong the 30% highest rated companies in the industry
20212025
Debt / equity
0.15×
StrongAmong the 30% highest rated companies in the industry
20212025
Sector performance
25 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Operating marginVery strong
Among the 20% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery strong
Among the 20% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Very strong
Among the 20% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very strong
Among the 10% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very strong
Among the 10% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very strong
Among the 10% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioStrong
Among the 30% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioStrong
Among the 30% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 20% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityAverage
Around the average of companies in the same industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalStrong
Among the 40% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioStrong
Among the 30% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioStrong
Among the 30% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityStrong
Among the 30% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityStrong
Among the 30% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery strong
Among the 10% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery strong
Among the 10% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 10% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery strong
Among the 10% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverStrong
Among the 30% highest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalStrong
Among the 40% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JE Chief Executive Officer | Chief Executive Officer | 2023 |
JE Chief Auditor | Chief Auditor | 2024 |
Former (4)
MP Chief Executive Officer | Chief Executive Officer | 2020 – 2023 |
EM Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
JM Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
KL Chief Auditor | Chief Auditor | 2020 – 2024 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
BM Chairman | Chairman | 2021 |
SA Board of Directors | Board of Directors | 2021 |
PF Board of Directors | Board of Directors | 2021 |
KE Board of Directors | Board of Directors | 2020 |
RB Board of Directors | Board of Directors | 2026 |
Former (5)
NR Chairman | Chairman | 2020 – 2021 |
KC Board of Directors | Board of Directors | 2020 – 2020 |
JN Board of Directors | Board of Directors | 2020 – 2022 |
LE Board of Directors | Board of Directors | 2020 – 2021 |
CH Board of Directors | Board of Directors | 2020 – 2021 |
Shareholders
Active legal ownersNo shareholder data available.
Related companies
Company hierarchy
Sprint Bioscience AB 
Fragment Finans ABBoard network connections
Board members of Sprint Bioscience AB also hold positions in 297 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Erik Niclas Bergenmo | Chief Auditor | 157 companiesMany roles |
| Karl Leonard Daun | Chief Auditor | 72 companiesMany roles |
| Nils Rune Nordlander | Chairman | 22 companiesMany roles |
| Per Fredrik Lehmann | Board of Directors | 10 companiesMany roles |
| Björn Magnus Sjöstrand | Chairman | 7 companiesMany roles |
| Lars Erik Björk | Board of Directors | 6 companiesMany roles |
| Rikard Boive Andreas Lindenhierta | Board of Directors | 6 companiesMany roles |
| Erik Myung-Jin Kinnman | Chief Executive Officer | 4 companies |
| Jan-Erik Nyström | Board of Directors | 4 companies |
| Mathias Per Skalmstad | Chief Executive Officer | 2 companies |
| Svein Arild Mathisen | Board of Directors | 2 companies |
| Johan Emil Emilsson | Chief Executive Officer | 1 company |
| Jessica Marie Martinsson | Chief Executive Officer | 1 company |
| Karen Elisabeth From | Board of Directors | 1 company |
| Karin Charlotta Liljebris | Board of Directors | 1 company |
| Charlotte Hilda Helena Leife | Board of Directors | 1 company |
Frequently asked questions
What is the Org number of Sprint Bioscience AB?
Sprint Bioscience AB is registered with Bolagsverket / SCB under Org 5567897557.
What is the revenue of Sprint Bioscience AB?
Sprint Bioscience AB reported revenue of SEK 167.2m in 2025.
How many employees does Sprint Bioscience AB have?
Sprint Bioscience AB employs 41 people as of the latest annual report.
Who is the CEO of Sprint Bioscience AB?
Johan Emil Emilsson is the CEO of Sprint Bioscience AB, in role since 2023.
Who is the chairman of Sprint Bioscience AB?
Björn Magnus Sjöstrand chairs the board of Sprint Bioscience AB, in role since 2021.
Where is Sprint Bioscience AB headquartered?
Sprint Bioscience AB's registered address is Hälsovägen 7.